Antileukemic Potential of Momordica charantia Seed Extracts on Human Myeloid Leukemic HL60 Cells

Abstract EN

Momordica charantia (bitter gourd) has been used in the traditional system of medicine for the treatment of various diseases.

Anticancer activity of M.

charantia extracts has been demonstrated by numerous in vitro and in vivo studies.

In the present study, we investigated the differentiation inducing potential of fractionated M.

charantia seed extracts in human myeloid HL60 cells.

We found that the HL60 cells treated with the fractionated seed extracts differentiated into granulocytic lineage as characterized by NBT staining, CD11b expression, and specific esterase activity.

The differentiation inducing principle was found to be heat-stable, and organic in nature.

The differentiation was accompanied by a downregulation of c-myc transcript, indicating the involvement of c-myc pathway, at least in part, in differentiation.

Taken together these results indicate that fractionated extracts of M.

charantia seeds possess differentiation inducing activity and therefore can be evaluated for their potential use in differentiation therapy for leukemia in combination with other inducers of differentiation.